₹58.5*
MRP ₹65
10% off
₹55.25*
MRP ₹65
15% CB
₹9.75 cashback(15%)
Free Delivery
With Circle membership
(Inclusive of all Taxes)
This offer price is valid on orders above ₹800. Apply coupon PHARMA10/PHARMA18 (excluding restricted items)
coupon
Prescription drugWhats That
Synonym :
GLIMEPIRIDE+METFORMIN HYDROCHLORIDE
Composition :
GLIMEPIRIDE-1MG + METFORMIN-500MG
Manufacturer/Marketer :
Anthem Bio Pharma
Consume Type :
ORAL
Return Policy :
Not Returnable
Expires on or after :
Secure Payment
Trusted by 8 Crore Indians
Genuine Products
Author Details
Disclaimer
While we strive to provide complete, accurate, and expert-reviewed content on our 'Platform', we make no warranties or representations and disclaim all responsibility and liability for the completeness, accuracy, or reliability of the aforementioned content. The content on our platform is for informative purposes only, and may not cover all clinical/non-clinical aspects. Reliance on any information and subsequent action or inaction is solely at the user's risk, and we do not assume any responsibility for the same. The content on the Platform should not be considered or used as a substitute for professional and qualified medical advice. Please consult your doctor for any query pertaining to medicines, tests and/or diseases, as we support, and do not replace the doctor-patient relationship.
Customers Also Bought
Alcohol
Unsafe
You are recommended to avoid consumption of alcohol with Enristas-1MF Tablet as it may increase the risk of lactic acidosis (accumulation of lactic acid in the body).
Pregnancy
Unsafe
Enristas-1MF Tablet is not recommended for pregnant women as it may harm the unborn baby. Please consult a doctor if you are pregnant or planning for pregnancy.
Breast Feeding
Unsafe
Avoid breastfeeding while taking Enristas-1MF Tablet as it may be excreted in breastmilk and cause adverse effects in the baby. Therefore, please consult a doctor before using Enristas-1MF Tablet if you are breastfeeding.
Driving
Caution
Enristas-1MF Tablet may decrease alertness in some people. Therefore, drive only if you are alert after taking Enristas-1MF Tablet .
Liver
Caution
Take Enristas-1MF Tablet with caution, especially if you have a history of Liver diseases/conditions. The dose may be adjusted by your doctor as required.
Kidney
Caution
Take Enristas-1MF Tablet with caution, especially if you have a history of Kidney diseases/conditions. The dose may be adjusted by your doctor as required.
Children
Unsafe
Enristas-1MF Tablet is not recommended for children as the safety and effectiveness were not established.
Product Substitutes
Drug-Drug Interactions
GlimepirideVilazodone
Severe
GlimepirideGrepafloxacin
Severe
Drug-Drug Interactions
Login/Sign Up
GlimepirideVilazodone
Severe
How does the drug interact with Enristas-1MF Tablet:
Taking Enristas-1MF Tablet with Vilazodone may increase the risk of low blood sugar.
How to manage the interaction:
Although there is a possible interaction, Enristas-1MF Tablet can be taken with Vilazodone if prescribed by the doctor. Consult the prescriber if you experience symptoms of low blood sugar such as headache, dizziness, drowsiness, nervousness, confusion, tremor, nausea, hunger, weakness, perspiration, palpitation, and rapid heartbeat. Do not discontinue the medications without consulting a doctor.
Taking Enristas-1MF Tablet with Vilazodone may increase the risk of low blood sugar.
How to manage the interaction:
Although there is a possible interaction, Enristas-1MF Tablet can be taken with Vilazodone if prescribed by the doctor. Consult the prescriber if you experience symptoms of low blood sugar such as headache, dizziness, drowsiness, nervousness, confusion, tremor, nausea, hunger, weakness, perspiration, palpitation, and rapid heartbeat. Do not discontinue the medications without consulting a doctor.
GlimepirideGrepafloxacin
Severe
How does the drug interact with Enristas-1MF Tablet:
Co-administration of Enristas-1MF Tablet with Grepafloxacin can sometimes affect blood glucose levels. Both hyperglycemia (high blood glucose) and, less frequently, hypoglycemia (low blood glucose) have been reported.
How to manage the interaction:
Although there is a possible interaction between Enristas-1MF Tablet and Grepafloxacin, you can take these medicines together if prescribed by a doctor. If you experience any of these symptoms - low blood sugar, headache, dizziness, sleepiness, confusion, shaking, feeling hungry, weak, heart racing, high blood sugar, low blood sugar, serious infections, bleeding, feeling anxious, feeling sick or very thirsty - make sure to call a doctor right away. Do not stop using any medications without talking to a doctor.
Co-administration of Enristas-1MF Tablet with Grepafloxacin can sometimes affect blood glucose levels. Both hyperglycemia (high blood glucose) and, less frequently, hypoglycemia (low blood glucose) have been reported.
How to manage the interaction:
Although there is a possible interaction between Enristas-1MF Tablet and Grepafloxacin, you can take these medicines together if prescribed by a doctor. If you experience any of these symptoms - low blood sugar, headache, dizziness, sleepiness, confusion, shaking, feeling hungry, weak, heart racing, high blood sugar, low blood sugar, serious infections, bleeding, feeling anxious, feeling sick or very thirsty - make sure to call a doctor right away. Do not stop using any medications without talking to a doctor.
GlimepirideKetoprofen
Severe
How does the drug interact with Enristas-1MF Tablet:
Taking Ketoprofen with Enristas-1MF Tablet may increase the risk of hypoglycemia (low blood sugar).
How to manage the interaction:
Although there is a possible interaction, Enristas-1MF Tablet can be taken with Ketoprofen if prescribed by the doctor. Consult the prescriber if you experience symptoms of low blood sugar such as headache, dizziness, drowsiness, nervousness, confusion, tremor, nausea, hunger, weakness, perspiration, palpitation, and rapid heartbeat. Do not taking the medications without consulting a doctor.
Taking Ketoprofen with Enristas-1MF Tablet may increase the risk of hypoglycemia (low blood sugar).
How to manage the interaction:
Although there is a possible interaction, Enristas-1MF Tablet can be taken with Ketoprofen if prescribed by the doctor. Consult the prescriber if you experience symptoms of low blood sugar such as headache, dizziness, drowsiness, nervousness, confusion, tremor, nausea, hunger, weakness, perspiration, palpitation, and rapid heartbeat. Do not taking the medications without consulting a doctor.
GlimepirideCitalopram
Severe
How does the drug interact with Enristas-1MF Tablet:
Taking Enristas-1MF Tablet with Citalopram may increase the risk of low blood sugar.
How to manage the interaction:
Although there is a possible interaction, Enristas-1MF Tablet can be taken with Citalopram if prescribed by the doctor. Consult the prescriber if you experience symptoms of low blood sugar such as headache, dizziness, drowsiness, nervousness, confusion, tremor, nausea, hunger, weakness, perspiration, palpitation, and rapid heartbeat. Do not discontinue the medications without consulting a doctor.
Taking Enristas-1MF Tablet with Citalopram may increase the risk of low blood sugar.
How to manage the interaction:
Although there is a possible interaction, Enristas-1MF Tablet can be taken with Citalopram if prescribed by the doctor. Consult the prescriber if you experience symptoms of low blood sugar such as headache, dizziness, drowsiness, nervousness, confusion, tremor, nausea, hunger, weakness, perspiration, palpitation, and rapid heartbeat. Do not discontinue the medications without consulting a doctor.
GlimepirideBumetanide
Severe
How does the drug interact with Enristas-1MF Tablet:
Bumetanide may interfere with blood glucose control and reduce the effectiveness of Enristas-1MF Tablet.
How to manage the interaction:
Although there is a possible interaction, Enristas-1MF Tablet can be taken with bumetanide if prescribed by the doctor. Monitoring of blood glucose levels is advised.
Bumetanide may interfere with blood glucose control and reduce the effectiveness of Enristas-1MF Tablet.
How to manage the interaction:
Although there is a possible interaction, Enristas-1MF Tablet can be taken with bumetanide if prescribed by the doctor. Monitoring of blood glucose levels is advised.
GlimepirideGatifloxacin
Severe
How does the drug interact with Enristas-1MF Tablet:
Taking Enristas-1MF Tablet with Gatifloxacin may affect blood glucose levels. Both low blood glucose and, less frequently, high blood glucose have been reported.
How to manage the interaction:
Gatifloxacin is not recommended for patients with diabetes, however, it can be taken if advised by a doctor. Consult the prescriber if you experience symptoms such as nervousness, confusion, headache, dizziness, drowsiness, tremors, nausea, hunger, weakness, perspiration, palpitation, rapid heartbeat, increased urination, increased thirst, and increased hunger. Maintaining blood glucose levels is advised. Do not discontinue the medications without consulting a doctor.
Taking Enristas-1MF Tablet with Gatifloxacin may affect blood glucose levels. Both low blood glucose and, less frequently, high blood glucose have been reported.
How to manage the interaction:
Gatifloxacin is not recommended for patients with diabetes, however, it can be taken if advised by a doctor. Consult the prescriber if you experience symptoms such as nervousness, confusion, headache, dizziness, drowsiness, tremors, nausea, hunger, weakness, perspiration, palpitation, rapid heartbeat, increased urination, increased thirst, and increased hunger. Maintaining blood glucose levels is advised. Do not discontinue the medications without consulting a doctor.
GlimepirideEnoxacin
Severe
How does the drug interact with Enristas-1MF Tablet:
Taking Enristas-1MF Tablet with Enoxacin, may affect blood glucose levels which may lead to hypoglycemia (low blood glucose) and hyperglycemia (high blood glucose).
How to manage the interaction:
Taking Enristas-1MF Tablet with Enoxacin together can possibly result in an interaction, but it can be taken if a doctor has advised it. This can be a good thing if you need help lowering your blood sugar, but it can also be a problem if it goes too low. If you notice any of these symptoms, it's important to contact a doctor right away. Do not stop using any medications without a doctor's advice.
Taking Enristas-1MF Tablet with Enoxacin, may affect blood glucose levels which may lead to hypoglycemia (low blood glucose) and hyperglycemia (high blood glucose).
How to manage the interaction:
Taking Enristas-1MF Tablet with Enoxacin together can possibly result in an interaction, but it can be taken if a doctor has advised it. This can be a good thing if you need help lowering your blood sugar, but it can also be a problem if it goes too low. If you notice any of these symptoms, it's important to contact a doctor right away. Do not stop using any medications without a doctor's advice.
GlimepirideSunitinib
Severe
How does the drug interact with Enristas-1MF Tablet:
Taking Enristas-1MF Tablet with sunitinib may increase the risk of low blood sugar.
How to manage the interaction:
Although there is a possible interaction, Enristas-1MF Tablet can be taken with sunitinib if prescribed by the doctor. Consult the prescriber if you experience symptoms if low blood sugar such as headache, dizziness, drowsiness, nervousness, confusion, tremor, nausea, hunger, weakness, perspiration, palpitation, and rapid heartbeat. Do not discontinue the medications without consulting a doctor.
Taking Enristas-1MF Tablet with sunitinib may increase the risk of low blood sugar.
How to manage the interaction:
Although there is a possible interaction, Enristas-1MF Tablet can be taken with sunitinib if prescribed by the doctor. Consult the prescriber if you experience symptoms if low blood sugar such as headache, dizziness, drowsiness, nervousness, confusion, tremor, nausea, hunger, weakness, perspiration, palpitation, and rapid heartbeat. Do not discontinue the medications without consulting a doctor.
GlimepirideAminolevulinic acid
Severe
How does the drug interact with Enristas-1MF Tablet:
Aminolevulinic acid sensitizes your skin to bright lights and combining it with other medications that can also have this effect (i.e., photosensitivity) such as Enristas-1MF Tablet may increase the risk of a severe sunburn.
How to manage the interaction:
Taking Enristas-1MF Tablet with Aminolevulinic acid together can possibly result in an interaction, but it can be taken if a doctor has advised it. If you notice that your skin is very sensitive to sunlight or if you have a really bad sunburn, it's important to contact a doctor right away. Do not stop using any medications without talking to a doctor.
Aminolevulinic acid sensitizes your skin to bright lights and combining it with other medications that can also have this effect (i.e., photosensitivity) such as Enristas-1MF Tablet may increase the risk of a severe sunburn.
How to manage the interaction:
Taking Enristas-1MF Tablet with Aminolevulinic acid together can possibly result in an interaction, but it can be taken if a doctor has advised it. If you notice that your skin is very sensitive to sunlight or if you have a really bad sunburn, it's important to contact a doctor right away. Do not stop using any medications without talking to a doctor.
GlimepirideLevofloxacin
Severe
How does the drug interact with Enristas-1MF Tablet:
Co-administration of Enristas-1MF Tablet with Levofloxacin can affect blood glucose levels. Both hyperglycemia (high blood glucose) and, less frequently, hypoglycemia (low blood glucose) have been reported.
How to manage the interaction:
Co-administration of Levofloxacin with Enristas-1MF Tablet can result in an interaction, it can be taken if a doctor has advised it. Consult the prescriber if you experience dizziness, drowsiness, headache, nervousness, confusion, tremors, nausea, hunger, weakness, perspiration, palpitation, and rapid heartbeat, increased urination, increased thirst, or increased hunger. Monitoring of blood glucose levels is advised. Do not discontinue the medications without consulting a doctor.
Co-administration of Enristas-1MF Tablet with Levofloxacin can affect blood glucose levels. Both hyperglycemia (high blood glucose) and, less frequently, hypoglycemia (low blood glucose) have been reported.
How to manage the interaction:
Co-administration of Levofloxacin with Enristas-1MF Tablet can result in an interaction, it can be taken if a doctor has advised it. Consult the prescriber if you experience dizziness, drowsiness, headache, nervousness, confusion, tremors, nausea, hunger, weakness, perspiration, palpitation, and rapid heartbeat, increased urination, increased thirst, or increased hunger. Monitoring of blood glucose levels is advised. Do not discontinue the medications without consulting a doctor.
Drug-Food Interactions
No Drug - Food interactions found in our database. Some may be unknown. Consult your doctor for what to avoid during medication.
Drug-Food Interactions
Login/Sign Up
Drug-Diseases Interactions
GLIMEPIRIDE-1MG+METFORMIN-500MGHypertensive heart and renal disease
Severe
GLIMEPIRIDE-1MG+METFORMIN-500MGUnspecified kidney failure
Severe
Drug-Diseases Interactions
Login/Sign Up
GLIMEPIRIDE-1MG+METFORMIN-500MGHypertensive heart and renal disease
Severe
How does the disease interact with Enristas-1MF Tablet:
When compared to diet alone or diet plus insulin, the use of oral hypoglycemic medications may be associated with an increased risk of cardiovascular mortality. This alert is based on the University Group Diabetes Programme (UGDP) project, a long-term prospective clinical investigation aimed to assess the efficacy of glucose-lowering medications in preventing or delaying vascular problems in non-insulin-dependent diabetes patients. Patients treated for 5 to 8 years with diet with a fixed dose of either tolbutamide (a sulfonylurea) or phenformin (a biguanide) had a cardiovascular death risk nearly 2.5 times that of patients treated with diet alone, resulting in the cessation of both therapies in the research. Regardless of how these findings are interpreted, doctors and patients should be aware of the possibility.
How to manage the interaction:
The use of oral hypoglycemic agents may be associated with an increased risk of heart problems. Let the doctor know if you have heart problems.
When compared to diet alone or diet plus insulin, the use of oral hypoglycemic medications may be associated with an increased risk of cardiovascular mortality. This alert is based on the University Group Diabetes Programme (UGDP) project, a long-term prospective clinical investigation aimed to assess the efficacy of glucose-lowering medications in preventing or delaying vascular problems in non-insulin-dependent diabetes patients. Patients treated for 5 to 8 years with diet with a fixed dose of either tolbutamide (a sulfonylurea) or phenformin (a biguanide) had a cardiovascular death risk nearly 2.5 times that of patients treated with diet alone, resulting in the cessation of both therapies in the research. Regardless of how these findings are interpreted, doctors and patients should be aware of the possibility.
How to manage the interaction:
The use of oral hypoglycemic agents may be associated with an increased risk of heart problems. Let the doctor know if you have heart problems.
GLIMEPIRIDE-1MG+METFORMIN-500MGUnspecified kidney failure
Severe
How does the disease interact with Enristas-1MF Tablet:
Sulfonylureas are metabolised in the liver and eliminated in the urine and faeces as metabolites (some of which have pharmacologic activity). Patients with poor liver and/or renal function who are treated with sulfonylureas may be exposed to increased serum drug concentrations, increasing the risk of severe hypoglycemia episodes. In the context of hepatic impairment, gluconeogenic ability may be reduced, adding to the risk. Sulfonylurea therapy should be used with caution in people who have liver or kidney illness. It is possible that lower dosages and longer intervals between dosage adjustments will be required. If hypoglycemia occurs during treatment, it may be prolonged in these patients due to slower medication metabolism and/or excretion.
How to manage the interaction:
In patients with kidney problems, severe hypoglycemic episodes may occur. Therapy should be administered cautiously in patients with renal disease.
Sulfonylureas are metabolised in the liver and eliminated in the urine and faeces as metabolites (some of which have pharmacologic activity). Patients with poor liver and/or renal function who are treated with sulfonylureas may be exposed to increased serum drug concentrations, increasing the risk of severe hypoglycemia episodes. In the context of hepatic impairment, gluconeogenic ability may be reduced, adding to the risk. Sulfonylurea therapy should be used with caution in people who have liver or kidney illness. It is possible that lower dosages and longer intervals between dosage adjustments will be required. If hypoglycemia occurs during treatment, it may be prolonged in these patients due to slower medication metabolism and/or excretion.
How to manage the interaction:
In patients with kidney problems, severe hypoglycemic episodes may occur. Therapy should be administered cautiously in patients with renal disease.
GLIMEPIRIDE-1MG+METFORMIN-500MGOther disorders of adrenal gland
Moderate
How does the disease interact with Enristas-1MF Tablet:
Hypoglycemia is a common side effect of insulin and/or oral hypoglycemic medications. Patients who are debilitated or malnourished, those with defective counterregulatory mechanisms (e.g., autonomic neuropathy and adrenal or pituitary insufficiency), and those receiving beta-adrenergic blocking agents should exercise caution when using these drugs.
How to manage the interaction:
Care should be taken in patients who may be particularly susceptible to the development of hypoglycemic episodes during treatment.
Hypoglycemia is a common side effect of insulin and/or oral hypoglycemic medications. Patients who are debilitated or malnourished, those with defective counterregulatory mechanisms (e.g., autonomic neuropathy and adrenal or pituitary insufficiency), and those receiving beta-adrenergic blocking agents should exercise caution when using these drugs.
How to manage the interaction:
Care should be taken in patients who may be particularly susceptible to the development of hypoglycemic episodes during treatment.
GLIMEPIRIDE-1MG+METFORMIN-500MGAnaemia due to enzyme disorders
Moderate
How does the disease interact with Enristas-1MF Tablet:
In patients with glucose 6-phosphate dehydrogenase (G6PD) impairment, sulfonylureas can cause hemolytic anaemia. In individuals with G6PD deficiency, these medicines should be administered with caution, and a non-sulfonylurea option should be considered. Postmarketing reports of hemolytic anaemia in patients receiving these medications who did not have known G6PD deficiency have been received.
How to manage the interaction:
Therapy should be used with caution in patients with glucose 6-phosphate dehydrogenase (G6PD) deficiency. The use of a non-sulfonylurea alternative should be considered.
In patients with glucose 6-phosphate dehydrogenase (G6PD) impairment, sulfonylureas can cause hemolytic anaemia. In individuals with G6PD deficiency, these medicines should be administered with caution, and a non-sulfonylurea option should be considered. Postmarketing reports of hemolytic anaemia in patients receiving these medications who did not have known G6PD deficiency have been received.
How to manage the interaction:
Therapy should be used with caution in patients with glucose 6-phosphate dehydrogenase (G6PD) deficiency. The use of a non-sulfonylurea alternative should be considered.
GLIMEPIRIDE-1MG+METFORMIN-500MGOther disorders of fluid, electrolyte and acid-base balance
Moderate
How does the disease interact with Enristas-1MF Tablet:
Treatment with sulfonylureas may cause hyponatremia in individuals who are taking other drugs or have medical disorders that cause hyponatremia, or it may stimulate the secretion of antidiuretic hormone. Certain sulfonylureas have been linked to the syndrome of inappropriate antidiuretic hormone (SIADH) secretion, and these medications may enhance the peripheral (antidiuretic) action of ADH and/or increase ADH release. Caution should be exercised when treating individuals who have hyponatremia or are at increased risk of developing hyponatremia, such as the elderly, those using diuretics, or those who are volume-depleted.
How to manage the interaction:
Caution should be used when treating patients with low sodium or at greater risk of developing low sodium such as elderly patients, patients taking diuretics or those who are volume-depleted.
Treatment with sulfonylureas may cause hyponatremia in individuals who are taking other drugs or have medical disorders that cause hyponatremia, or it may stimulate the secretion of antidiuretic hormone. Certain sulfonylureas have been linked to the syndrome of inappropriate antidiuretic hormone (SIADH) secretion, and these medications may enhance the peripheral (antidiuretic) action of ADH and/or increase ADH release. Caution should be exercised when treating individuals who have hyponatremia or are at increased risk of developing hyponatremia, such as the elderly, those using diuretics, or those who are volume-depleted.
How to manage the interaction:
Caution should be used when treating patients with low sodium or at greater risk of developing low sodium such as elderly patients, patients taking diuretics or those who are volume-depleted.
Have a query?